Lifecore Biomedical (LFCR) Q3 2024 earnings summary

Executive summary

• Transitioned to a pure-play CDMO focused on sterile injectable pharmaceuticals after divesting food businesses as of May 28, 2023.

• Operates as a single reportable segment, leveraging expertise in HA manufacturing and aseptic filling.

• Strategic partnerships and expanded manufacturing agreements, notably with Alcon, drive business.

Financial highlights

• Q3 FY24 total revenues rose 35% year-over-year to $35.7M; nine-month revenues up 25% to $90.4M.

• Q3 gross profit increased 39% to $11.9M; gross margin improved to 33.3% from 32.2% year-over-year.

• Net income for Q3 was $15.6M, compared to a net loss of $36.5M in Q3 FY23; nine-month net income was $19.1M versus a $60.3M loss.

• Adjusted EBITDA for Q3 was $6.4M, up from $4.5M in Q3 FY23.

Outlook and guidance

• Management expects sufficient liquidity for at least the next twelve months, supported by cash, operations, and credit facility availability.

• Ongoing capital expenditures to support growth, with $15.3M invested in the first nine months.